The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
TBF, following this recent sp pattern, its been worth taking early trades to de-risk a hold position on this too, until results arrive. I think a lot will have been using these swings before it settles down.
Chrishnar, if you want a basic valuation, Finncap have provided this recently for SNG. I would use it as a basic guide personally. I , like loads of others on here, have researched this as much as possible. You have to also look hard into this, soak up as much info as you can find from good sources and then assess your appetite for risk (v) gain .
Great article thanks TM. I think SNG are the only trial with inhaled delivery though ? Route of delivery can be decisive in efficacy though.
Personally, I think successful trial data for us will see SG001 merge into another rapid combo trial with a potent anti-viral. Just my own view...
Thanks SGD, not read that one. Your summary is correct IMO. CV19 is worse due to quicker, more rapid growth ( leading to higher viral load = more exhaled = higher spread ), and causing the cyt. storm that damages lung tissue = lower O2 saturation = organ failure. Therefore more likely to be transmissible successfully and potentially higher morbidity for those developing the cyt. storm response. I think it’s still unknown though why some remain asymptomatic
It’s about getting statistically significant and robust results here that stand up to peer scrutiny. SNG have been bringing SNG001 closer to finish line for years.... they know the pressure for Tx of CV19, but theyll hold out any release until they get the above. Not impossible to get updates on trial progression eg numbers / sites etc maybe ??
Issue with that G-Man11 is that those figures are, I believe and abstract and not gleaned from a full double blind trial which I understand Gilead themselves have cautioned drawing too much from ? Lets hope they turn out to be promising tho'.
SNG is totally different and the sp will reflect a new drug and delivery if it's effective here.
I wouldnt read the lack of leaks from SNG as bad news - far from it IMO. If I thought I had a winner in a small company like them, Id want to be really sure I had evidenced it all without question before I went out on a limb . Even great new drugs often dont make it to market for many reasons - different times now (sadly). DYOR
This is being tested as both Therapeutic AND Prophylactic - see part E.6.1 and E.6.2 of the link below;
hTTps://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB
Also, looking at the NIHR listings for COVID 19 - of the 27, only 8 are interventions which are in progress, of which SG016 is one - now upgraded to urgent.
Exactly, I was hoping for 55p, but part topped up at 58. That’ll be irrelevant soon.
Look at just the EGM news and sp reaction....think this drift is largely due to no trial news....... patience is needed. It’s just as the company planned.
Holding because I feel researched and done as much DD as I can. I think this could be dropped to mid 50’s before trial results possibly. Obs, it rides on sentiment every day till then rather than facts. Risk (v) gain.
Fortune favors the brave...... sorry not Soros, W.Buffet......might be Die Hard ;-)). DYOR
Agreed. I’m sure I read that was the case.....speedier and clean route to the funding they required.
Irritating to not be offered it at 35p, but on the other hand, PI’s won’t remember that figure, if this performs as we all hope.
Recommended article posted yesterday by clinicians - hope it's helpful to people here, especially anyone expecting news quickly.
Synairgen are included and it's written and run by medics / researchers ( mostly UK). As a former healthcare provider, I think it's informative for investors here. For me, it's very reassuring that there have been no leaks /false promises / company ramps etc and I have confidence that the company are acting very responsibly here in keeping everything under wraps until the appropriate time. See what you think ?
hTTps://www.stemlynsblog.org/covid19-why-we-need-evidence-based-medicine-ebm-more-than-ever-in-a-pandemic-st-emlyns/
To try to draw a line under this....
The Recovery Trial website did mention beta interferon as no.4 BUT stated in brackets ( not part of this trial )......,aka very confusing !!
I think Thursdays edit ( and protocol / patient consent downloads ) was just to remove the confusion and add the Azo. drug
IMO, nothing sinister, just clarification since clinical staff were obs getting their patient consent forms etc here etc.
As far as I’m aware ( please update if incorrect);
SG016 trial is ongoing but now expanded into more sites. Double blind tests = low chance of leaks ( I’m not aware of anything )
Just have to do your research, and decide on risk v reward here.
Time to move on ?
hTTps://www.dailymail.co.uk/news/article-8208229/Pharmaceutical-firm-donate-two-million-tablets-malaria-drug-worlds-largest-COVID-19-trial.html
Think it’s an updated article, but still only yesterday ...
I agree John, I think I was getting nervous this pm.....but then thats their plan isnt it ! I did think it was just tidying up the website and also that the SG016 trial had already started within it's own parameters.
I do have great hopes in the product and also confidence in the running of the trial. GLA.
Noticed that beta interferon has been removed from the Recovery Trial website as the 4th on that list and replaced with Azithromycin. There is a subsequent protocol update on the site too as of today.
I know SNG001 wasn't in this trial, ( but was on that list for some odd reason ? ) ........so Im hoping that its removal today is just tidying up /clarification, not anything else.